USP Drug Quality Pilot Program Underway in Sub-Saharan Africa - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Drug Quality Pilot Program Underway in Sub-Saharan Africa


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

On Apr. 18, 2011, scientists from the national laboratories of five African nations gathered in Accra, Ghana, to take part in a week of technical training put on by the US Pharmacopeia (USP) that will teach them how to detect substandard and counterfeit medicines.

USP is providing participants from Ethiopia, Ghana, Kenya, Senegal, and Sierra Leone with pharmaceutical reference standards, documentary standards, and technical writing training in an effort to improve help the quality of those countries’ medicines.  The instruction is a part of a pilot Technical Assistance Program (TAP) that was introduced earlier this year and funded by USP.

USP developed TAP based on feedback from participants about topics they wanted to see addressed most.  National laboratories in these countries often have to rely on unreliable or outdated standards to analyze medicines. The laboratories also may not be equipped to offer analysts the scientific training needed to appropriately analyze medicines.

As a result, accurate outcomes may not be obtained when questionable substances are tested. “Having a team of scientists trained in essential analytical techniques is a fundamental aspect of a well-functioning regulatory system that protects domestic drug supply,” said Patrick Lukulay, director of the PQM program in a USP press release.

The objective of the training is to improve the technical competence of the scientists and familiarize participants with information contained in the USP-NF, including how to use the information, according to the USP release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here